Johns Hopkins covers how GLP-1 medications are changing weight loss treatment. Only the title is available, so tap through for the details.
Recap by typeshit. Full story at Johns Hopkins University.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Dr Palter shares new research he calls the biggest look yet at GLP-1 medicines in pregnancy, and says the results suggest risks are low.
Frank Campbell Jr., 61, says Lilly's labels didn't warn enough about stomach paralysis. Lilly says its FDA-approved labels already flag severe GI reactions.
Loading…